Mirae Asset Global Etfs Holdings Ltd. Verve Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 144,027 shares of VERV stock, worth $793,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144,027Holding current value
$793,588% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
173Shares Held
74.7MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$68 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$36.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$29 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$25 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$21.3 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $330M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...